Considerations on safety concerns about citalopram prescribing.
作者信息
Sheeler Robert D, Ackerman Michael J, Richelson Elliott, Nelson Thomas K, Staab Jeffrey P, Tangalos Eric G, Dieser Lisa M, Cunningham Julie L
机构信息
Department of Family Medicine, Mayo Clinic, Rochester, MN 55905, USA.
出版信息
Mayo Clin Proc. 2012 Nov;87(11):1042-5. doi: 10.1016/j.mayocp.2012.07.009. Epub 2012 Sep 24.
Abstract
摘要
相似文献
1
Considerations on safety concerns about citalopram prescribing.
Mayo Clin Proc. 2012 Nov;87(11):1042-5. doi: 10.1016/j.mayocp.2012.07.009. Epub 2012 Sep 24.
2
Comments and questions regarding the safety of citalopram.
Mayo Clin Proc. 2013 Apr;88(4):420. doi: 10.1016/j.mayocp.2013.01.023.
3
In reply.
Mayo Clin Proc. 2013 Apr;88(4):420. doi: 10.1016/j.mayocp.2013.01.020.
4
Citalopram (Celexa) and QT interval prolongation.
Med Lett Drugs Ther. 2012 Sep 3;54(1398):71-2.
5
Emergence of electric shock-like sensations on escitalopram discontinuation.
J Clin Psychopharmacol. 2008 Jun;28(3):359-60. doi: 10.1097/JCP.0b013e3181727534.
6
Escitalopram-associated serotonin toxicity.
J Clin Psychopharmacol. 2007 Apr;27(2):229-30. doi: 10.1097/01.jcp.0000264977.64120.43.
7
Citalopram approved for treatment of depression.
Am J Health Syst Pharm. 1998 Oct 1;55(19):1963. doi: 10.1093/ajhp/55.19.1963.
8
Deciding which selective serotonin reuptake inhibitor to prescribe.
BMJ. 1995 Dec 16;311(7020):1641. doi: 10.1136/bmj.311.7020.1641a.
9
Yawning as a dose-dependent side effect of treatment with escitalopram.
Neurologia. 2013 Nov-Dec;28(9):589-90. doi: 10.1016/j.nrl.2012.05.007. Epub 2012 Jul 12.
10
Prescribe escitalopram instead of citalopram.
Am J Med. 2013 Jun;126(6):e21. doi: 10.1016/j.amjmed.2012.10.024.
引用本文的文献
1
Design and methods of the 'monitoring outcomes of psychiatric pharmacotherapy' (MOPHAR) monitoring program - a study protocol.
BMC Health Serv Res. 2019 Feb 14;19(1):125. doi: 10.1186/s12913-019-3951-2.
2
Monitoring of somatic parameters at outpatient departments for mood and anxiety disorders.
PLoS One. 2018 Aug 21;13(8):e0200520. doi: 10.1371/journal.pone.0200520. eCollection 2018.
3
Anxiolytic effects of ketamine in animal models of posttraumatic stress disorder.
Psychopharmacology (Berl). 2015 Feb;232(4):663-72. doi: 10.1007/s00213-014-3697-9. Epub 2014 Sep 18.
本文引用的文献
1
Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review.
Gen Hosp Psychiatry. 2012 Mar-Apr;34(2):210.e13-5. doi: 10.1016/j.genhosppsych.2011.10.005. Epub 2011 Nov 30.
2
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.
Circulation. 2010 Mar 2;121(8):1047-60. doi: 10.1161/CIRCULATIONAHA.109.192704. Epub 2010 Feb 8.
3
Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents.
Am J Psychiatry. 2007 Sep;164(9):1356-63. doi: 10.1176/appi.ajp.2007.07030454.
4
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Am J Psychiatry. 2006 Jan;163(1):28-40. doi: 10.1176/appi.ajp.163.1.28.
5
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
Control Clin Trials. 2004 Feb;25(1):119-42. doi: 10.1016/s0197-2456(03)00112-0.
6
A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes.
Pharmacol Toxicol. 2003 Aug;93(2):77-81.
7
Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.
Psychiatr Clin North Am. 2003 Jun;26(2):457-94, x. doi: 10.1016/s0193-953x(02)00107-7.
Zotero 插件